BEPRIDIL HYDROCHLORIDE ANHYDROUS

US Previously Marketed

First approved in 1990

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H34N2O.ClH
Molecular Weight	403.0
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BEPRIDIL HYDROCHLORIDE ANHYDROUS

Structure Search

SMILES

Cl.CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3

InChI

InChIKey=JXBBWYGMTNAYNM-UHFFFAOYSA-N

InChI=1S/C24H34N2O.ClH/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22;/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	C24H34N2O
Molecular Weight	366.5396
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rxlist.com/vascor-drug.htm
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/bepridil.html | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075 | https://www.ncbi.nlm.nih.gov/pubmed/1280569

Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It has inhibitory effects on both the slow calcium and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. It is used to treat hypertension (high blood pressure), angina (chest pain), sustained atrial fibrillation and tachyarrhythmia. The most common side effects were upper gastrointestinal complaints (nausea, dyspepsia or GI distress), diarrhea, dizziness, asthenia and nervousness. Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride. In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants. Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride. Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-secretase (BACE) 5 Target ID: CHEMBL2111390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Inhibitor 8504	6.0 µM [IC50]
Gamma-secretase 21 Target ID: CHEMBL2094135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Modulator 846
potassium sodium-activated channel subfamily T member 1 3 Target ID: 57582.0 Gene Symbol: KCNT1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16876206	Inhibitor 8504	1.0 µM [IC50]
Voltage and receptor operated calcium channels 3 Target ID: Voltage and receptor operated calcium channels Sources: http://www.rxlist.com/vascor-drug.htm	Blocker 555

Conditions

Condition	Modality	Highest Phase	Product
Chronic stable angina 10 Sources: http://www.rxlist.com/vascor-drug.htm	Primary	Approved 8583	BEPRICOR Approved Use Bepridil hydrochloride is indicated for the treatment of chronic stable angina (classic effort-associated angina).
Hypertension 575 Sources: https://www.drugs.com/mtm/bepridil.html	Primary	Approved 8583	BEPRICOR Approved Use Bepridil is used to treat hypertension (high blood pressure) and to treat angina (chest pain).
Atrial fibrillation 131 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8583	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.
Tachyarrhythmia 17 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8583	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.

C_max

Value	Dose	Co-administered	Analyte	Population
806 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
4.87 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
38.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3875635			BEPRIDIL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Weakness, Lightheadedness... AEs leading to discontinuation/dose reduction: Weakness (2 patients) Lightheadedness (1 patient) Syncopal attack (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Electrocardiogram QTc interval prolonged... AEs leading to discontinuation/dose reduction: Electrocardiogram QTc interval prolonged (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Diarrhea (1 patient) Anorexia (1 patient) Bigeminy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (1 patient) Bradycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (grade 5, 1 patient) Bradycardia (1 patient) Electrocardiogram QTc interval prolonged (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

AEs

AE	Significance	Dose	Population
Lightheadedness	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Syncopal attack	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Weakness	2 patients Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Electrocardiogram QTc interval prolonged	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Anorexia	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bigeminy	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Diarrhea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Nausea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bradycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Bradycardia	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Electrocardiogram QTc interval prolonged	4 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	grade 5, 1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507 substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2E1 1060	CYP1A2 1197 P-gp 2052 BCRP 697

Drug as perpetrator

Target	Modality	Activity
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19702529/	yes
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32906709/	yes

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28210973/	no
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
P-gp 2052	substrate 4014 Sources: https://www.futuremedicine.com/doi/abs/10.1517/14622416.2.4.401	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY565364	https://www.001chemical.com/chem/64706-54-3
3B Scientific (Wuhan) Corp	3B2-0571	http://www.3bsc.com/index/pro_info.php?id=19927
abcr GmbH	AB542520	http://www.abcr.com/shop/en/AB542520
Achemo Scientific Limited	AC-11145	http://www.achemo.com/search/?Keyword=64706-54-3
AHH Chemical co.,ltd	API-1541	http://www.ahhchemical.com/product/API-1541.html
AK Scientific, Inc. (AKSCI)	K042	http://www.aksci.com/item_detail.php?cat=K042
Angel Pharmatech	AG121309	http://www.angelpharmatech.com/64706-54-3.html
BLD Pharm	BD116381	http://www.bldpharm.com/products/64706-54-3.html
ChemMol	30105085	http://www.chemmol.com/chemmol/30105085.html
ChemMol	99124623	http://www.chemmol.com/chemmol/99124623.html
Chemspace	CSSB00000047941	https://chem-space.com/CSSB00000047941
CSNpharm	CSN10416	https://www.csnpharm.com/products/bepridil.html
Debye Scientific	DB-054717	http://www.debyesci.com/cas_64706-54-3.html
Finetech	FT-0630749	http://www.finetechnology-ind.com/prod/detail/pub/64706-54-3.html
Glentham Life Sciences	GP4395	http://www.glentham.com/products/product/GP4395/
Lab Network	LN00330174	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00330174
Molcore	MC565364	https://www.molcore.com/product/64706-54-3
Smolecule	S520991	http://www.smolecule.com/products/s520991
Smolecule	S772535	https://www.smolecule.com/products/s772535
THE BioTek	bt-261730	https://www.thebiotek.com/product/inhibitors/bt-261730
THE BioTek	bt-311849	https://www.thebiotek.com/product/others/bt-311849
Vesino Industrial Co Ltd	VA10387	http://www.vsnchem.com/goto/product/23859/

PubMed

Title	Date	PubMed
Cancer chemopreventive activities of S-3-1, a synthetic derivative of danshinone.	2001	11355772
Effect of nilvadipine in weak acidic medium by 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay.	2001	11304937
Blocking effect of bepridil on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.	2001 Apr	11388640
A new antioxidant monoterpene glycoside, alpha-benzoyloxypaeoniflorin from Paeonia suffruticosa.	2001 Apr	11339628
Ionic mechanisms of aglycemic axon injury in mammalian central white matter.	2001 Apr	11323524
New bis-catechols 5-lipoxygenase inhibitors.	2001 Feb	11249115
In vitro evaluation of the antioxidant activity and biomembrane interaction of the lazaroid U-74389G.	2001 Feb 9	11388688
Antioxidant principles from Bauhinia tarapotensis.	2001 Jul	11473417
Electron spin resonance assessment of the antioxidant potential of medicinal plants. Part I. Contribution of anthocyanosides and flavonoids to the radical scavenging ability of fruit and herbal teas.	2001 Jul-Aug	11693734
Evaluation of the absorption, excretion, and metabolism of the antihypertensive agent RWJ-26899 in male and female CR Wistar rats and Beagle dogs.	2001 Jul-Sep	11695715
Cyclooxygenase-inhibitory and antioxidant constituents of the aerial parts of Antirhea acutata.	2001 Jun 18	11412982
Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical method.	2001 Mar	11268111
The antioxidant activity of the essential oils of Artemisia afra, Artemisia abyssinica and Juniperus procera.	2001 Mar	11268106
Antioxidant activities of buckwheat hull extract toward various oxidative stress in vitro and in vivo.	2001 Mar	11256471
Relationship between effects of phenolic compounds on the generation of free radicals from lactoperoxidase-catalyzed oxidation of NAD(P)H or GSH and their DPPH scavenging ability.	2001 Mar	11253920
Traumatic axonal injury induces calcium influx modulated by tetrodotoxin-sensitive sodium channels.	2001 Mar 15	11245677
Radical scavenging activity against 1,1-diphenyl-2-picrylhydrazyl of ascorbic acid 2-glucoside (AA-2G) and 6-acyl-AA-2G.	2001 May	11383624
A novel series of thromboxane A2 synthetase inhibitors with free radical scavenging and anti-peroxidative activities.	2001 May	11383607
Effect of the antianginal drug bepridil on intracellular Ca2+ release and extracellular Ca2+ influx in human neutrophils.	2001 May	11379049
Screening of chemiluminescence constituents of cereals and DPPH radical scavenging activity of gamma-oryzanol.	2001 May-Jun	11400261
Scavenging of reactive oxygen species by chlorophyllin: an ESR study.	2001 Nov	11767414
Inhibitory effect of bepridil on hKv1.5 channel current: comparison with amiodarone and E-4031.	2001 Nov 2	11711026
Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities.	2001 Nov-Dec	11911276
Antioxidative components from the aerial parts of Lactuca scariola L.	2001 Oct	11693545
Effect of calcium antagonists, calcium channel blockers and calmodulin inhibitors on the growth and encystation of Entamoeba histolytica and E. invadens.	2001 Oct	11688889
DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants.	2001 Oct	11642334
Scavenging of free radicals, antimicrobial, and cytotoxic activities of the Maillard reaction products of beta-lactoglobulin glycated with several sugars.	2001 Oct	11600062
Antioxidant activities of dioscorin, the storage protein of yam (Dioscorea batatas Decne) tuber.	2001 Oct	11600050
Identification and antioxidant activity of novel chlorogenic acid derivatives from bamboo (Phyllostachys edulis).	2001 Oct	11600002
Interaction of bepridil with the cardiac troponin C/troponin I complex.	2001 Sep 28	11591369
Antioxidative activity and safety of the 50 ethanolic extract from red bean fermented by Bacillus subtilis IMR-NK1.	2002 Apr 10	11929313
Antioxidant capacities of ten edible North American plants.	2002 Feb	11807968
Interaction of digoxin with antihypertensive drugs via MDR1.	2002 Feb 15	11895100
Antioxidant enzymes and DPPH-radical scavenging activity in chilled and heat-shocked rice (Oryza sativa L.) seedlings radicles.	2002 Jan 30	11804522
Free radical scavenging activity of red ginseng aqueous extracts.	2002 Mar 20	11882354
Free radical studies of ellagic acid, a natural phenolic antioxidant.	2002 Mar 27	11902978
Antioxidant properties of ferulic acid and its related compounds.	2002 Mar 27	11902973
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.	2002 Nov	12419934
Sodium-calcium exchange influences the response to endothelin-1 in lens epithelium.	2003 Sep	12887970
Bioequivalence study of two formulations of simvastatin tablets in healthy Thai volunteers.	2004	14979606
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.	2004 Feb 20	14975710
Evidence for a protective role played by the Na+/Ca2+ exchanger in cerebral ischemia induced by middle cerebral artery occlusion in male rats.	2004 Mar	14975699

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 200 mg once a day. Maintenance dose: 300-400 mg once a day.

Route of Administration: Oral

In Vitro Use Guide

In APP-overexpressing HEK293 cells lower Ab38, Ab40 and Ab42 generation was detected after Bepridil treatment (30 uM) for 16 h.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:43:55 GMT 2025` Edited by `admin` on `Mon Mar 31 21:43:55 GMT 2025`
Record UNII	2TN7FF3W4M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE MONOHYDROCHLORIDE

Preferred Name

English

BEPRIDIL HYDROCHLORIDE ANHYDROUS

Common Name

English

1-PYRROLIDINEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Code System Code Type Description

SMS_ID

100000091249